secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-07-14T13:23:23+00:00
Accession:  0001437749-26-023480
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.03, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex files 1:22 reverse stock split to address Nasdaq bid price deficiency; faces delisting risk
--------------------------------------------------------------------------------

- Reverse stock split at 1:22 ratio effective July 16, 2026; shares outstanding to reduce from ~11.1M to ~505K.
- Received Nasdaq delisting notice on June 10, 2026 for failing to maintain $1.00 bid price; requested hearing.
- Acclaim-1 Phase 2a enrolling; Acclaim-3 Phase 2 expansion enrolling, interim analysis expected H1 2027.
- Identified TROP-2 and PTEN as predictive biomarkers for REQORSA; plan to evaluate high TROP-2 expression.
- No guarantee reverse split will regain compliance; risk of delisting and adverse impact on stock price and capital access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926023480/0001437749-26-023480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926023480/gnpx20260630_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-023480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer